TransThera Sciences (Nanjing), Inc. Showcases Pioneering Research on Endocrine Resistance in HR+ Breast Cancer and Updates on Tinengotinib at AACR 2026

Highlights from the Announcement

• TransThera Sciences (Nanjing), Inc. presented groundbreaking research at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
• The company disclosed lineage reprogramming as a key resistance mechanism to endocrine therapy in hormone receptor positive (HR+) breast cancer.
• New preclinical data for Tinengotinib (TT-00420), a dual FGFR-JAK inhibitor, was unveiled, showing its potential to restore sensitivity to endocrine therapy in resistant HR+ breast cancer models.
• Ongoing Phase II clinical trial of Tinengotinib in combination with endocrine therapy for advanced HR+ breast cancer was highlighted.
• Tinengotinib continues to advance globally, having received Orphan Drug Designation (ODD), Fast Track Designation, and Breakthrough Therapy Designation in several jurisdictions.

Key Details for Shareholders and Investors

1. Scientific Breakthrough: The research presented at AACR 2026 reveals that lineage plasticity, specifically a transition from luminal to basal cell types with downregulation of estrogen and progesterone receptors (ER/PR), underlies resistance to endocrine therapy in HR+ breast cancer. This mechanism was observed both in primary tumors and was even more pronounced in metastatic lesions, particularly in malignant pleural effusions.

2. Mechanistic Insights and Therapeutic Innovation: Using cutting-edge single-cell transcriptomics, the research team found that both therapy-induced and microenvironment-driven resistance converge on the activation of FGFR and JAK signaling pathways, leading to the repression of key luminal genes (ESR1, PGR). This insight provides a clear target for overcoming resistance.

3. Tinengotinib (TT-00420) – A Promising Dual Inhibitor: Tinengotinib, an internally developed multi-kinase inhibitor, targets FGFRs/VEGFRs, Aurora A/B kinases, and Janus kinases (JAK). Preclinical data shows that Tinengotinib effectively restores luminal identity and resensitizes resistant cancer models to endocrine therapy both in vitro and in vivo. This supports the strategy of using dual FGFR-JAK blockade to counteract resistance in HR+ breast cancer.

4. Clinical Development and Regulatory Status: Tinengotinib is at the NDA (New Drug Application) stage with the NMPA (China’s regulatory agency) and is being studied in multiple global clinical trials for various solid tumors, including cholangiocarcinoma (CCA), prostate cancer, breast cancer, and liver cancer. The drug has received significant regulatory recognitions:

• Orphan Drug Designation (ODD) and Fast Track Designation from the US FDA for CCA
• Orphan Drug Designation from the European Medicines Agency (EMA) for biliary tract cancer
• Inclusion in China NMPA’s Priority Review List and Breakthrough Therapy Designation List

A Phase II trial of Tinengotinib in combination with endocrine therapy for advanced HR+ breast cancer is currently ongoing.

Potential Impact on Share Value

The announcement is potentially price-sensitive for several reasons:

• The identification of a new, targetable resistance mechanism in HR+ breast cancer represents a major scientific and clinical advance.
• Positive preclinical results for Tinengotinib in overcoming endocrine resistance may boost investor confidence in its commercial and clinical prospects, especially given the large market for breast cancer therapies.
• The drug’s progress through regulatory pathways and its multiple designations in the US, EU, and China indicate significant growth potential and expedited paths to market in several indications.
• Ongoing clinical trials and the move towards Phase II for a combination therapy in a high-need area could lead to further value inflection points pending successful results.

Important Note for Investors

Warning: There is no assurance that Tinengotinib or other products referenced will ultimately be successfully developed and marketed by TransThera Sciences (Nanjing), Inc. Investors should be aware that further clinical and regulatory milestones must be met before commercialization is realized.

Corporate Governance

As of the date of the announcement, the board of TransThera Sciences (Nanjing), Inc. is comprised of Dr. Frank Wu (Chairman and CEO), Mr. Wu Di (Executive Director), Ms. Jia Zhongxin (Non-Executive Director), and three Independent Non-Executive Directors: Mr. Li Shu Pai, Ms. Chui Hoi Yam, and Ms. Zheng Zhelan.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The development and commercialization of pharmaceutical products involve significant risks, including clinical, regulatory, and business uncertainties. Investors should conduct their own due diligence and seek professional advice before making investment decisions.

View TRANSTHERA-B Historical chart here